dr. bendell discusses pembrolizumab in crc
Published 6 years ago • 88 plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
9:02
pembrolizumab in msi-h crc tumors
-
0:50
dr. bendell discusses two studies in braf-mutated crc
-
0:55
dr. bendell discusses the importance of testing for braf status in crc patients
-
1:07
dr. bendell on the next steps following progression on immunotherapy in msi-h crc
-
1:27
dr. grothey on fda approval of pembrolizumab in msi-high crc
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
0:52
dr. bendell on a phase ii study of onartuzumab in combination with bevacizumab for mcrc
-
1:08
dr. bendell on fda approval of regorafenib in liver cancer
-
3:41
a look ahead: dr. bendell discusses latest advancements in immunotherapy
-
0:49
dr. bang on pembrolizumab for advanced gastric cancer
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
1:05
dr. taieb discusses primary tumor location in crc
-
0:49
dr. bendell discusses a phase iii study of apatinib in gastric cancer
-
1:50
dr. levy discusses pembrolizumab in nsclc
-
1:12
dr. lenz on choosing between regorafenib and tas-102 in crc
-
1:44
dr. kopetz discusses the treatment of braf-mutant crc
-
1:28
dr. bekaii-saab on the response rate of pembrolizumab in msi-h crc
-
1:20
dr. corcoran on targeting her2 amplification in crc
-
1:16
findings for pembrolizumab plus mfolfox6 in advanced crc